Centerbridge Partners’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Centerbridge Partners’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-50,000	Closed	-$3.19K	–	18
2022 Q4	$3.19K	Hold	50,000	–	–	﹤0.01%	16
2022 Q3	$4K	Hold	50,000	–	–	﹤0.01%	21
2022 Q2	$5K	Hold	50,000	–	–	﹤0.01%	26
2022 Q1	$12K	Hold	50,000	–	–	﹤0.01%	27
2021 Q4	$33K	Hold	50,000	–	–	﹤0.01%	46
2021 Q3	$33K	Hold	50,000	–	–	﹤0.01%	44
2021 Q2	$43K	Hold	50,000	–	–	﹤0.01%	47
2021 Q1	$30K	Buy	+50,000	New	+$35.3K	﹤0.01%	46

Centerbridge Partners's BIOTW Position: Q1 2023 in Review

Centerbridge Partners sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 50,000 shares — an estimated $3.19K sold.

Centerbridge Partners first reported a position in BIOTW in Q1 2021 and held it in 8 quarters. The position peaked at $43K in Q2 2021. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

Centerbridge Partners reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
Centerbridge Partners sold 50,000 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $3.19K.
Centerbridge Partners first reported a position in Biotech Acquisition Company Warrant in Q1 2021 and held it in 8 quarters.
Centerbridge Partners's Biotech Acquisition Company Warrant position peaked at $43K in Q2 2021.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on Centerbridge Partners's 13F filing for Q1 2023, filed 15 May 2023.